Company profile: Bristol Myers Squibb
1.1 - Company Overview
Company description
- Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
Products and services
- Eliquis (Apixaban): An oral anticoagulant employed to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- Opdivo (Nivolumab): A monoclonal antibody employed in cancer immunotherapy to treat various types of cancer by inhibiting the PD-1 protein on T cells
- Yervoy (Ipilimumab): A monoclonal antibody employed in cancer treatment that works by activating the immune system to attack cancer cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bristol Myers Squibb
Altor BioScience
HQ: United States
Website
- Description: Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (N‑803), an IL‑15 receptor agonist for non‑muscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); Tri‑Ad5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altor BioScience company profile →
Biotest
HQ: Germany
Website
- Description: Provider of plasma proteins and biotherapeutic drugs for haematology, clinical immunology and intensive care medicine, developing, manufacturing and marketing immunoglobulins and clotting factors, with a value chain extending from pre-clinical and clinical development to worldwide marketing and distribution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotest company profile →
Amerita
HQ: United States
Website
- Description: Provider of specialty infusion services focused on delivering complex pharmaceutical products and clinical services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amerita company profile →
Antares Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products and drug-delivery technologies leveraging proprietary platforms, including ENHANZE® for subcutaneous delivery that can reduce hours-long IV infusions to minutes-long injections; subcutaneous and intramuscular auto-injectors; HYLENEX® recombinant to facilitate dispersion and absorption of injected drugs; XYOSTED® CIII testosterone enanthate injection; and a partner auto-injector pipeline used in five approved therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antares Pharma company profile →
United Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology products and patient support services, including an Expanded Access Program for investigational drugs; ASSIST Access Solutions for medicine access and financial assistance; Archways educational resources for patients on inhaled or oral treprostinil via phone or video; and MyOldMeds.com for secure storage and disposal of unwanted or expired medications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full United Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bristol Myers Squibb
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bristol Myers Squibb
2.2 - Growth funds investing in similar companies to Bristol Myers Squibb
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bristol Myers Squibb
4.2 - Public trading comparable groups for Bristol Myers Squibb
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →